Cargando…

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model

Debate continues as to the role of combination antibiotic therapy for the management of Pseudomonas aeruginosa infections. We studied the extent of bacterial killing by and the emergence of resistance to meropenem and amikacin as monotherapies and as a combination therapy against susceptible and res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avent, Minyon L., McCarthy, Kate L., Sime, Fekade B., Naicker, Saiyuri, Heffernan, Aaron J., Wallis, Steven C., Paterson, David L., Roberts, Jason A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241727/ https://www.ncbi.nlm.nih.gov/pubmed/35442072 http://dx.doi.org/10.1128/spectrum.00525-22

Ejemplares similares

Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa
por: Heffernan, Aaron J., et al.
Publicado: (2021)

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model
por: Mohd Sazlly Lim, Sazlyna, et al.
Publicado: (2022)

Morphological and Bactericidal Effects of Amikacin, Meropenem and Imipenem on Pseudomonas aeruginosa
por: Moghoofei, Mohsen, et al.
Publicado: (2015)

Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis
por: Heffernan, Aaron, et al.
Publicado: (2021)

Oral or intravenous antibiotics?
por: McCarthy, Kate, et al.
Publicado: (2020)

Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy
por: Sime, Fekade Bruck, et al.
Publicado: (2016)

Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model
por: Islam, Kamrul, et al.
Publicado: (2022)

Breakthrough Bacteremia with Meropenem-resistant Pseudomonas aeruginosa in Hematologic Malignancy Patients Receiving Levofloxacin Prophylaxis
por: Hakki, Morgan, et al.
Publicado: (2017)

Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin
por: Mabrouk, Samar S., et al.
Publicado: (2023)

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam
por: Sime, Fekade B., et al.
Publicado: (2018)

Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa
por: Nussbaumer-Pröll, A., et al.
Publicado: (2022)

Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant Pseudomonas aeruginosa
por: Tang, Xi-kang, et al.
Publicado: (2022)

The comparative effects of erythromycin and amikacin on acute respiratory Pseudomonas aeruginosa infection
por: Yazdanian, Mohsen, et al.
Publicado: (2022)

Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant Klebsiella pneumoniae in vitro
por: Yu, Lan, et al.
Publicado: (2019)

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2016)

A contemporary case series of Pseudomonas aeruginosa infective endocarditis
por: Walczak, Andrew, et al.
Publicado: (2023)

Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia
por: Ammar, Mona Ahmed, et al.
Publicado: (2018)

Meta-analysis: combination of meropenem vs ceftazidime and amikacin for empirical treatment of cancer patients with febrile neutropenia
por: Wang, Ying, et al.
Publicado: (2021)

Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis
por: Molinaro, Mariadelfina, et al.
Publicado: (2018)

Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant Pseudomonas aeruginosa
por: Farhan, Sara Mahmoud, et al.
Publicado: (2021)

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection
por: Wang, Yuhang, et al.
Publicado: (2022)

Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study
por: Babich, Tanya, et al.
Publicado: (2022)

Fosfomycin (FOS) Plus Meropenem (MER) Suppresses Resistance Emergence Against P. aeruginosa (PA) PAO1 in the Hollow Fiber Infection Model (HFIM)
por: Louie, Arnold, et al.
Publicado: (2017)

Impact of minocycline, polymyxin B, meropenem, and amikacin on growth-prevention of Acinetobacter baumannii with various biofilm-forming capabilities
por: Beganovic, Maya, et al.
Publicado: (2017)

Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
por: Olivares, Elodie, et al.
Publicado: (2017)

The predictive potential of different molecular markers linked to amikacin susceptibility phenotypes in Pseudomonas aeruginosa
por: Nageeb, Wedad M., et al.
Publicado: (2022)

Proteomic analysis of ceftazidime and meropenem-exposed Pseudomonas aeruginosa ATCC 9027
por: Ngo, Hong Loan, et al.
Publicado: (2023)

Successful Treatment of Serious Meningitis Caused by Extremely Carbapenem-Resistant Enterobacter cloacae (MIC≥16mg/L) with i.v. Meropenem and i.v. Amikacin Plus Intraventricular Amikacin
por: He, Zheng, et al.
Publicado: (2019)

521. Comparative In Vitro Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of Pseudomonas aeruginosa
por: Patel, Twisha S, et al.
Publicado: (2019)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa
por: Nasomsong, Worapong, et al.
Publicado: (2022)

In vitro potency of amikacin against carbapenem-resistant Pseudomonas aeruginosa: A target for nebulization strategy?
por: Cuba, Gabriel T., et al.
Publicado: (2022)

Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii
por: Dahdouh, E., et al.
Publicado: (2014)

Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in Pseudomonas aeruginosa
por: Hassuna, Noha Anwar, et al.
Publicado: (2020)

Draft Genome Sequence of an IMP-7-Producing Pseudomonas aeruginosa Bloodstream Infection Isolate from Australia
por: McCarthy, K. L., et al.
Publicado: (2017)

Draft Genome Sequences of Two Pseudomonas aeruginosa Bloodstream Infection Isolates Associated with Rapid Patient Death
por: McCarthy, K. L., et al.
Publicado: (2017)

Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
por: Motos, Ana, et al.
Publicado: (2023)

Effect of combined colistin and meropenem against meropenem resistant Acinetobacter baumannii and Pseudomonas aeruginosa by checkerboard method: A cross sectional analytical study
por: Gunalan, Anitha, et al.
Publicado: (2021)

Where to from here? Identifying and prioritising future directions for addressing drug-resistant infection in Australia
por: Merlo, Gregory, et al.
Publicado: (2021)

Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm
por: Alam, Farhana, et al.
Publicado: (2020)

Transcriptional profiling of Pseudomonas aeruginosa mature single- and dual-species biofilms in response to meropenem
por: Alam, Farhana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k92omuas1q5fs8321laqh3i2tr